ABOUT US

Enzyvant works to develop breakthrough biotechnologies and transformative therapies for people with devastating rare diseases. The Enzyvant pipeline includes investigational regenerative medicine therapies for T cell–implicated conditions and enzyme therapies for acid ceramidase deficiency. Enzyvant’s investigational therapies have been granted numerous regulatory designations in the US and Europe, including Breakthrough Therapy (BTD), Regenerative Medicine Advanced Therapy (RMAT), Rare Pediatric Disease, and Orphan Drug designations. People with rare diseases are fighting for their lives. Enzyvant is dedicated to helping patients win that fight.

On December 27, 2019, Sumitomo Dainippon Pharma Co., Ltd. acquired from Roivant 100% of Sumitovant Biopharma, a newly formed company, and Roivant’s ownership interest in the five subsidiary companies, including Enzyvant, that comprise Sumitovant.

LEADERSHIP

Rachelle Jacques

Chief Executive Officer

Rachelle joined Enzyvant as CEO from Alexion Pharmaceuticals, Inc., where she most recently served as Senior Vice President and Global Franchise Head of Complement across therapeutic areas of hematology, nephrology, and neurology. She brings broad experience in US and Global commercial leadership, including multiple high-profile product launches in rare diseases. Previously, Rachelle was Vice President of US Hematology Marketing at Shire and Baxalta, and Vice President, Business Operations for the Global Bioscience Business Unit at Baxter International. Rachelle has lived and worked in the US, Belgium, and China. She started her career in finance and has a BA in Business Administration with an emphasis in accounting from Alma College. Rachelle also serves on the board of Corbus Pharmaceuticals.

Jeb Ledell

Chief Operating Officer

Jeb joined Enzyvant as COO having served previously as COO at Compass Therapeutics and Horizon Discovery Group, leading operations at both businesses through multiple changes in scale. He has held multiple technology, operational, and development roles at Zalicus, a development-stage pain and inflammation therapeutics company.

Jeb has devoted more than 2 decades of his career to operational excellence, strategy, and product development and delivery for biotechnology and technology organizations. Jeb has a BS degree in Chemical Engineering from Worcester Polytechnic Institute.

Andrea Ashford-Hicks

Senior Vice President; Platform Head, T-cell Generation

Andrea brings to Enzyvant an extensive background working with both emerging and established biopharmaceutical companies to develop commercial strategy and prepare for product launches, as well as senior business development, sales, and marketing roles. Her experience includes positions as Head of Late-stage Asset Strategy and Commercial at Agenus, Vice President of US Oncology Marketing at EMD Serono, and Therapeutic Area Lead, Immunology and Oncology, New Business Development, North America at Johnson & Johnson. Earlier in her career, she held positions of increasing responsibility in marketing and sales at Pfizer, Allos Therapeutics, and Schering-Plough. Andrea received a BA in Biology from the University of Pennsylvania and a BS in Finance from the Wharton School of Business.

Jim Luterman, PhD

Senior Vice President; Platform Head, Recombinant Human Acid Ceramidase (rhAC)

Jim is a seasoned biotech/pharma executive who has spent more than 20 years working in program management and product commercialization with emerging and global biotech companies. His recent experience includes leading the integrated R&D team at OvaScience and, prior to that, heading up Early Development Teams at Shire. While at Shire, Jim led several cross-functional teams focused on rare/orphan diseases, including enzyme replacement therapies for lysosomal storage diseases. Previously, Jim guided program strategy for the flagship product at CombinatoRx and led the development team through multiple clinical trials. He also held positions in the New Product Commercialization group at Biogen, where he developed commercial analysis and recommendations for early-stage clinical development programs. Jim received his PhD in Neuroscience from Rutgers and was a postdoctoral fellow at Mount Sinai School of Medicine in New York City. He has an undergraduate degree in Biology/Psychology from Bucknell University.

Kevin Healy, PhD, RAC

Vice President; Regulatory Affairs and Quality

Kevin joined Enzyvant in 2018 and brings more than a dozen years of relevant regulatory affairs experience in the biotech and pharmaceutical industry to the company. Prior to joining Enzyvant, Kevin led the Global Regulatory Affairs department at Roivant Sciences. Kevin joined Roivant from Mallinckrodt Pharmaceuticals, where he was a Senior Director leading the Autoimmune and Rare Disease portfolio and led the development of several therapies through successful filings and registration. Kevin also spent several years at Gilead Sciences, where he served on global development teams for HBV and HCV treatments. Kevin received his BS in Biological Sciences from Cornell University, his PhD in Biochemistry from the University of Wisconsin–Madison, and completed a postdoctoral research fellowship in the Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill.

Contact us for more information